-Former Biotechnology Wall Street Leader to Play an Important Role in
the Growth of Regulus
Regulus Therapeutics LLC, a joint venture between Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc.
(Nasdaq: ISIS) formed to discover, develop, and commercialize
microRNA-based therapeutics, announced today the appointment of Garry
Menzel, Ph.D., as Executive Vice President of Corporate Development and
Finance. Dr. Menzel brings a very strong background in global
biotechnology finance practices to Regulus.
“We are delighted to welcome Garry to Regulus.
I have known Garry for many years and believe that his valuable insight
and extensive experience on Wall Street will complement our team of
experts in microRNA-based drug discovery and development,”
said Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive
Officer of Regulus. “We are very pleased that
we have been able to rapidly assemble a world-renowned Scientific
Advisory Board, a Board of Directors composed of industry leaders, and a
dynamic executive team committed to advancing the field of microRNAs.
This combined with the decades of work and key intellectual property
from Isis and Alnylam, have provided us with an unprecedented
opportunity to create a new class of high-impact drugs based on
microRNAs.”
“I am very excited to join the executive
management team of Regulus and have the opportunity to participate in
the development of a completely new class of therapeutics,”
said Garry Menzel, Ph.D. “I have seldom come
across a biotechnology company with as much potential to create value
from its revolutionary technology and patent estate. Not only does
Regulus benefit from the RNA therapeutics experience of Alnylam and
Isis, but the company also has an outstanding Scientific Advisory Board.
The Regulus vision to generate high-impact medicines from a proprietary
technology platform fits precisely with my views of the promise and
excitement of the biotechnology industry.”
Before joining Regulus, Dr. Menzel had a distinguished career on Wall
Street running the global biotechnology practices for Goldman Sachs and
Credit Suisse. He joined Goldman Sachs in 1994, where he was a Managing
Director and founding member of the Healthcare Group. In 2004, Dr.
Menzel joined Credit Suisse as a Managing Director. He served a broad
range of biotechnology and pharmaceutical clients around the world,
raising capital and negotiating merger agreements for some of the
industry’s most significant transactions.
Prior to his career on Wall Street, Dr. Menzel was a strategy consultant
for Bain & Company, working on a variety of projects in Europe and Asia.
Dr. Menzel earned a B.Sc. with Honors in Biochemistry from the Imperial
College of Science & Technology in 1985, a Ph.D. in Molecular Biology
from the University of Cambridge in 1988, and an M.B.A. from the
Stanford Graduate School of Business in 1994. He is an Associate of the
Royal College of Science. Dr. Menzel serves as a director on the board
of the Institute for Systems Biology and is an executive board member of
the Epilepsy Therapy Project, where he chairs the Business Advisory
Committee.
About microRNAs
microRNAs are a recently discovered class of genetically encoded small
RNAs, approximately 20 nucleotides in length, and are believed to
regulate the expression of a large number of human genes.
